Efficacy of Dupilumab in Atopic Dermatitis : The Patient's Perspective
de Bruin-Weller, Marjolein (University Medical Center Utrecht)
Merola, Joseph F. (Harvard Medical School)
Hong, Chih-ho (Probity Medical Research)
Serra-Baldrich, E (Institut d'Investigació Biomèdica Sant Pau)
Ettler, Karel (University Hospital Hradec Kralove (República Txeca))
Sierka, Debra (Sanofi Genzyme, Cambridge)
Delevry, Dimittri (Regeneron Pharmaceuticals. Inc)
Chen, Zhen (Regeneron Pharmaceuticals. Inc)
Rossi, Ana Beatris (Sanofi Genzyme, Cambridge)
Universitat Autònoma de Barcelona

Data:	2021
Resum:	Atopic dermatitis (AD), a predominantly type 2 inflammatory skin disease, affects approximately 2-5% of adults, with a high burden of disease. In moderate-to-severe AD, lesions can be extensive and pruritus intense with patients experiencing skin pain, sleep and mental health disturbances, and diminished quality of life (QoL). The objective of this study was to evaluate the efficacy of dupilumab for the treatment of AD from the patients' perspective using patient-reported outcome data from four clinical trials (CHRONOS, SOLO 1&2, and CAFÉ) in patients (N = 1553) receiving either the approved 300 mg q2w dupilumab with/without topical corticosteroids (TCS) dose or control (placebo or placebo + TCS). Patient Global Assessment of Disease Status (PGADS) was used to measure patients' well-being and Patient Global Assessment of Treatment Effect (PGATE) was used to measure treatment efficacy. Patients were asked "Considering all the ways in which your eczema affects you, indicate how well you are doing" to assess their perception of well-being and "How would you rate the way your eczema responded to the study medication?" to assess their perception of treatment effect. Possible responses for both metrics included poor, fair, good, very good, and excellent. In all four studies, a significantly higher proportion of dupilumab-treated patients reported "Good"/"Very Good"/"Excellent" disease status from week 2 through study end versus control (CHRONOS, 52 weeks: 69. 8% vs. 25. 1%; SOLO 1&2, 16 weeks: 59. 5% vs. 24. 6%; CAFÉ, 16 weeks: 84. 1% vs. 45. 4%; all P < 0. 0001), and significantly more dupilumab-treated patients reported "Good"/"Very Good"/"Excellent" treatment efficacy versus control (CHRONOS: 72. 6% vs. 24. 8%; SOLO 1&2: 65. 0% vs. 21. 1%; CAFÉ, 16 weeks: 85. 0% vs. 36. 1%; all P < 0. 0001). Adult patients with AD perceived that dupilumab with/without concomitant TCS was highly efficacious and improved overall disease status and well-being as early as week 2 and throughout treatment periods up to 1 year. The online version of this article (10. 1007/s13555-021-00621-w) contains supplementary material, which is available to authorized users.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Atopic dermatitis ; Dupilumab ; Patient perception ; Patient-reported outcomes ; Treatment efficacy
Publicat a:	Dermatology and Therapy, Vol. 11 (november 2021) , p. 2123-2131, ISSN 2190-9172

DOI: 10.1007/s13555-021-00621-w
PMID: 34767181

9 p, 713.2 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats